{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T14:08:38Z","timestamp":1792505318938,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2012,10,24]],"date-time":"2012-10-24T00:00:00Z","timestamp":1351036800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"},{"start":{"date-parts":[[2012,10,24]],"date-time":"2012-10-24T00:00:00Z","timestamp":1351036800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>While adalimumab is licensed for ankylosing spondylitis (AS), open uncontrolled studies suggest therapeutic efficacy of TNF-inhibitors in juvenile onset AS (JoAS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 32 patients aged 12 to 17 years with severe, active and refractory JoAS were enrolled in a multicenter, randomized, double-blind, placebo-controlled parallel study of 12 weeks, followed by open-label adalimumab until week 24 for all patients. ASAS40 was used as the primary, and ASAS20, PedACR and single items were used as the secondary outcome measures for the intention to treat population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 17 patients were randomized to receive adalimumab 40 mg\/2 weeks and 15 patients received placebo. Two patients (one of each group) discontinued prematurely due to insufficient efficacy and were labeled as non-responders. In the double-blind part, more patients on adalimumab achieved an ASAS40 at week 4 (41%), week 8 (53%) and week 12 (53%) than on placebo (20%, 33%, 33%), while differences at week 8 only reached borderline significance (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.05). Also, at 4, 8 and 12 weeks ASAS20\/PedACR30\/70 response rates were higher in the adalimumab group (53%\/53%\/29%; 59%\/76%\/41%; 53%\/65%\/53%) compared to placebo (27%\/27%\/7%; 27%\/33%\/13%; 33%\/40%\/27%). In the adalimumab group a significant decrease of all disease activity parameters was noted at week 12 and was even more pronounced at week 24. At week 12 the Bath Ankylosing Spondylitis Disease activity spinal inflammation score decreased by 65% (\n                      <jats:italic>P<\/jats:italic>\n                      &lt;0.001), the back pain score decreased by 50% (\n                      <jats:italic>P<\/jats:italic>\n                      &lt;0.005), the Bath AS Functional Index (BASFI) score decreased by 47% (\n                      <jats:italic>P<\/jats:italic>\n                      &lt;0.02), while the Childhood Health Assessment Questionnaire-Disability Index (CHAQ-DI) score improved by 65% (\n                      <jats:italic>P<\/jats:italic>\n                      &lt;0.005). ANCOVA analysis demonstrated superiority of adalimumab over placebo for the physician global assessment of disease activity, parents' global assessment of subject's overall well-being, active joint count (all\n                      <jats:italic>P<\/jats:italic>\n                      &lt;0.05) and erythrocyte sedimentation rate (ESR) (\n                      <jats:italic>P<\/jats:italic>\n                      &lt;0.01).\n                    <\/jats:p>\n                    <jats:p>During the 12-week controlled phase, 29 AEs occurred in 10 patients on placebo compared to 27 AEs in 11 patients on adalimumab. Injection site reactions were the most common adverse events. There were 17 various infections occurring in the double-blind phase, 8 on placebo, 9 on adalimumab and a further 19 in the open label period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Adalimumab was well tolerated and highly effective in a double-blind randomized trial in patients with JoAS. Treatment effects rapidly occurred and persisted for at least 24 weeks of treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>EudraCT 2007-003358-27.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/ar4072","type":"journal-article","created":{"date-parts":[[2012,10,24]],"date-time":"2012-10-24T12:16:21Z","timestamp":1351080981000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":77,"title":["Double-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvement"],"prefix":"10.1186","volume":"14","author":[{"given":"Gerd","family":"Horneff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigrid","family":"Fitter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Foeldvari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Minden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmin","family":"Kuemmerle-Deschner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolay","family":"Tzaribacev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelika","family":"Thon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Borte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"Ganser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf","family":"Trauzeddel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Iko","family":"Huppertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,10,24]]},"reference":[{"key":"3802_CR1","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/1529-0131(199801)41:1<58::AID-ART8>3.0.CO;2-G","volume":"41","author":"J Braun","year":"1998","unstructured":"Braun J, Bollow M, Remlinger G, Eggens U, Rudwaleit M, Distler A, Sieper J: Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum. 1998, 41: 58-67. 10.1002\/1529-0131(199801)41:1<58::AID-ART8>3.0.CO;2-G.","journal-title":"Arthritis Rheum"},{"key":"3802_CR2","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/S0889-857X(05)70348-3","volume":"23","author":"R Burgos-Vargas","year":"1997","unstructured":"Burgos-Vargas R, Pacheco-Tena C, Vazquez-Mellado J: Juvenile-onset spondyloarthropathies. Rheum Dis Clin North Am. 1997, 23: 569-598. 10.1016\/S0889-857X(05)70348-3.","journal-title":"Rheum Dis Clin North Am"},{"key":"3802_CR3","first-page":"1780","volume":"29","author":"HJ Baek","year":"2002","unstructured":"Baek HJ, Shin KC, Lee YJ, Kang SW, Lee EB, Yoo CD, Song YW: Juvenile onset ankylosing spondylitis (JAS) has less severe spinal disease course than adult onset ankylosing spondylitis (AAS): clinical comparison between JOAS and AAS in Korea. J Rheumatol. 2002, 29: 1780-1785.","journal-title":"J Rheumatol"},{"key":"3802_CR4","first-page":"2281","volume":"21","author":"A Calin","year":"1994","unstructured":"Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, Jenkinson T: A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol. 1994, 21: 2281-2285.","journal-title":"J Rheumatol"},{"key":"3802_CR5","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1002\/art.21174","volume":"53","author":"M Stone","year":"2005","unstructured":"Stone M, Warren RW, Bruckel J, Cooper D, Cortinovis D, Inman RD: Juvenile-onset ankylosing spondylitis is associated with worse functional outcomes than adult-onset ankylosing spondylitis. Arthritis Rheum. 2005, 53: 445-451. 10.1002\/art.21174.","journal-title":"Arthritis Rheum"},{"key":"3802_CR6","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1136\/ard.2007.072512","volume":"67","author":"LS Gensler","year":"2008","unstructured":"Gensler LS, Ward MM, Reveille JD, Learch TJ, Weisman MH, Davis JC: Clinical, radiographic and functional differences between juvenile-onset and adult-onset ankylosing spondylitis: results from the PSOAS cohort. Ann Rheum Dis. 2008, 67: 233-237. 10.1136\/ard.2007.072512.","journal-title":"Ann Rheum Dis"},{"key":"3802_CR7","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1136\/ard.2008.092304","volume":"68","author":"FD O'Shea","year":"2009","unstructured":"O'Shea FD, Boyle E, Riarh R, Tse SM, Laxer RM, Inman RD: Comparison of clinical and radiographic severity of juvenile-onset versus adult-onset ankylosing spondylitis. Ann Rheum Dis. 2009, 68: 1407-1412. 10.1136\/ard.2008.092304.","journal-title":"Ann Rheum Dis"},{"key":"3802_CR8","doi-asserted-by":"publisher","first-page":"246","DOI":"10.3109\/03009748309098542","volume":"12","author":"O Garcia-Morteo","year":"1983","unstructured":"Garcia-Morteo O, Maldonado-Cocco JA, Suarez-Almazor ME, Garay E: Ankylosing spondylitis of juvenile onset: comparison with adult onset disease. Scand J Rheumatol. 1983, 12: 246-248. 10.3109\/03009748309098542.","journal-title":"Scand J Rheumatol"},{"issue":"Suppl. 20","key":"3802_CR9","first-page":"137","volume":"20","author":"G Horneff","year":"2002","unstructured":"Horneff G, Burgos-Vargas R: TNF-\u03b1 antagonists for the treatment of juvenile-onset spondylarthritides. Clin Exp Rheumatol. 2002, 20 (Suppl. 20): 137-142.","journal-title":"Clin Exp Rheumatol"},{"key":"3802_CR10","first-page":"390","volume":"31","author":"RE Petty","year":"2001","unstructured":"Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, He X, Maldonado-Cocco J, Orozco-Alcala J, Prieur AM, Suarez-Almazor ME, Woo P: International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2001, 31: 390-392.","journal-title":"J Rheumatol"},{"key":"3802_CR11","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.1002\/art.11325","volume":"48","author":"JC Davis Jr","year":"2003","unstructured":"Davis JC, van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, Kivitz A, Fleischmann R, Inman R, Tsuji W, Enbrel Ankylosing Spondylitis Study Group: Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum. 2003, 48: 3230-3236. 10.1002\/art.11325.","journal-title":"Arthritis Rheum"},{"key":"3802_CR12","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1002\/art.21913","volume":"54","author":"D van der Heijde","year":"2006","unstructured":"van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, Dougados M, Reveille JD, Wong RL, Kupper H, Davis JC, ATLAS Study Group: Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006, 54: 2136-2146. 10.1002\/art.21913.","journal-title":"Arthritis Rheum"},{"key":"3802_CR13","first-page":"82","volume":"52","author":"D van der Heijde","year":"2005","unstructured":"van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, Braun J: Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum. 2005, 52: 82-91.","journal-title":"Arthritis Rheum"},{"key":"3802_CR14","unstructured":"Roguska MA, Keegan M, Labkovsky B: The nucleotide sequence of LU 200134, and a description and complete nucleotide sequence of the LU 200134 mammalian expression vector. In-house report - BASF Bioresearch Corporation: BBC\/M 9607+9713."},{"key":"3802_CR15","unstructured":"Sakorafas P, Kaymakcalan Z: Characterization of LU 200134: recombinant human TNF\u03b1 interaction kinetic rate constants by real-time biospecific interaction analysis (BIA). BASF Bioresearch Corporation. Report No. BBC\/I 9602."},{"key":"3802_CR16","unstructured":"Patil S: Pharmacokinetic evaluation: a supplement to final clinical study report DE005. In-house report, Knoll Pharmaceutical Company: DE005-PK."},{"key":"3802_CR17","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa0706290","volume":"359","author":"DJ Lovell","year":"2008","unstructured":"Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K, Nemcova D, Mouy R, Sandborg C, Bohnsack J, Elewaut D, Foeldvari I, Gerloni V, Rovensky J, Minden K, Vehe RK, Weiner LW, Horneff G, Huppertz HI, Olson NY, Medich JR, Carcereri-De-Prati R, McIlraith MJ, Giannini EH, Martini A, Pediatric Rheumatology Collaborative Study Group, Pediatric Rheumatology International Trials Organisation: Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008, 359: 810-820. 10.1056\/NEJMoa0706290.","journal-title":"N Engl J Med"},{"key":"3802_CR18","first-page":"526","volume":"4","author":"AM Manadan","year":"2003","unstructured":"Manadan AM, Block JA, Sequeira W: Mycobacteria tuberculosis peritonitis associated with etanercept therapy. Clin Exp Rheumatol. 2003, 4: 526-","journal-title":"Clin Exp Rheumatol"},{"key":"3802_CR19","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1056\/NEJMoa011110","volume":"345","author":"J Keane","year":"2001","unstructured":"Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM: Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001, 345: 1098-1104. 10.1056\/NEJMoa011110.","journal-title":"N Engl J Med"},{"key":"3802_CR20","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/S1473-3099(03)00545-0","volume":"3","author":"MA Gardam","year":"2003","unstructured":"Gardam MA, Keystone EC, Menzies R, Manners S, Skamene E, Long R, Vinh DC: Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis. 2003, 3: 148-155. 10.1016\/S1473-3099(03)00545-0.","journal-title":"Lancet Infect Dis"},{"key":"3802_CR21","first-page":"2055","volume":"31","author":"M Henrickson","year":"2004","unstructured":"Henrickson M, Reiff A: Prolonged efficacy of etanercept in refractory enthesitis-related arthritis. J Rheumatol. 2004, 31: 2055-2061.","journal-title":"J Rheumatol"},{"issue":"Suppl 9","key":"3802_CR22","first-page":"S91","volume":"50","author":"G Horneff","year":"2004","unstructured":"Horneff G, Schmeling H, Moebius D, Foeldvari I: Efficacy of etanercept in active refractory juvenile spondylarthropathy: prospective open study of 40 patients [abstract]. Arthritis Rheum. 2004, 50 (Suppl 9): S91-","journal-title":"Arthritis Rheum"},{"key":"3802_CR23","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s00296-003-0378-0","volume":"24","author":"H Schmeling","year":"2004","unstructured":"Schmeling H, Horneff G: Infliximab in two patients with juvenile ankylosing spondylitis. Rheumatol Int. 2004, 24: 173-176. 10.1007\/s00296-003-0378-0.","journal-title":"Rheumatol Int"},{"key":"3802_CR24","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jbspin.2008.03.008","volume":"76","author":"M Sulpice","year":"2009","unstructured":"Sulpice M, Deslandre CJ, Quartier P: Efficacy and safety of TNFalpha antagonist therapy in patients with juvenile spondyloarthropathies. Joint Bone Spine. 2009, 76: 24-27. 10.1016\/j.jbspin.2008.03.008.","journal-title":"Joint Bone Spine"},{"key":"3802_CR25","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1056\/NEJM200003163421103","volume":"342","author":"DJ Lovell","year":"2000","unstructured":"Lovell DJ, Giannini EH, Reiff A: Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Eng J Med. 2000, 342: 763-769. 10.1056\/NEJM200003163421103.","journal-title":"N Eng J Med"},{"key":"3802_CR26","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1002\/art.10710","volume":"48","author":"DJ Lovell","year":"2003","unstructured":"Lovell DJ, Giannini EH, Reiff A, Jones OY, Schneider R, Olson JC, Stein LD, Gedalia A, Ilowite NT, Wallace CA, Lange M, Finck BK, Burge DJ: Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis Rheum. 2003, 48: 218-226. 10.1002\/art.10710.","journal-title":"Arthritis Rheum"},{"key":"3802_CR27","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1136\/ard.2003.014886","volume":"63","author":"G Horneff","year":"2004","unstructured":"Horneff G, Schmeling H, Biedermann T, Foeldvari I, Ganser G, Girschick HJ, Hospach T, Huppertz HI, Keitzer R, K\u00fcster RM, Michels H, Moebius D, Rogalski B, Thon A, Paediatric Rheumatology Collaborative Group: The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis. 2004, 63: 1638-1644. 10.1136\/ard.2003.014886.","journal-title":"Ann Rheum Dis"},{"key":"3802_CR28","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1136\/ard.2007.087593","volume":"68","author":"G Horneff","year":"2009","unstructured":"Horneff G, De Bock F, Foeldvari I, Girschick HJ, Michels H, Moebius D, Schmeling H: Safety and efficacy of combination of Etanercept and Methotrexate compared to treatment with Etanercept only in patients with juvenile idiopathic arthritis (JIA). Preliminary data from the German JIA Registry. Ann Rheum Dis. 2009, 68: 519-525. 10.1136\/ard.2007.087593.","journal-title":"Ann Rheum Dis"},{"key":"3802_CR29","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1136\/ard.62.3.245","volume":"62","author":"P Lahdenne","year":"2003","unstructured":"Lahdenne P, Vahasalo P, Honkanen V: Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study. Ann Rheum Dis. 2003, 62: 245-247. 10.1136\/ard.62.3.245.","journal-title":"Ann Rheum Dis"},{"key":"3802_CR30","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1002\/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO;2-F","volume":"44","author":"JJ Anderson","year":"2001","unstructured":"Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M: Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum. 2001, 44: 1876-1886. 10.1002\/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO;2-F.","journal-title":"Arthritis Rheum"},{"key":"3802_CR31","first-page":"2286","volume":"21","author":"S Garrett","year":"1994","unstructured":"Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A: A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994, 21: 2286-2291.","journal-title":"J Rheumatol"},{"key":"3802_CR32","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1002\/1529-0131(199707)40:7<1202::AID-ART3>3.0.CO;2-R","volume":"40","author":"EH Giannini","year":"1997","unstructured":"Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DR, Martini A: Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 1997, 40: 1202-1209.","journal-title":"Arthritis Rheum"},{"key":"3802_CR33","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1007\/s003930050174","volume":"58","author":"J Ruof","year":"1999","unstructured":"Ruof J, Sangha O, Stucki G: Evaluation of a German version of the Bath Ankylosing Spondylitis Functional Index (BASFI) and Dougados Functional Index (D-FI). Z Rheumatol. 1999, 58: 218-225. 10.1007\/s003930050174.","journal-title":"Z Rheumatol"},{"key":"3802_CR34","doi-asserted-by":"publisher","first-page":"S292","DOI":"10.1002\/1529-0131(200106)44:6<1411::AID-ART235>3.0.CO;2-O","volume":"44","author":"A Reiff","year":"2001","unstructured":"Reiff A, Henrickson M: Prolonged efficacy of etanercept in refractory juvenile ankylosing spondylitis. Arthritis Rheum. 2001, 44: S292-","journal-title":"Arthritis Rheum"},{"key":"3802_CR35","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1002\/art.21121","volume":"52","author":"SM Tse","year":"2005","unstructured":"Tse SM, Burgos-Vargas R, Laxer RM: Anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondylarthropathy. Arthritis Rheum. 2005, 52: 2103-2108. 10.1002\/art.21121.","journal-title":"Arthritis Rheum"},{"issue":"Suppl ii","key":"3802_CR36","first-page":"69","volume":"67","author":"R Burgos-Vargas","year":"2008","unstructured":"Burgos-Vargas R, Casasola-Vargas J, Gutierrez-Suarez R, Vazquez Mellado J: A twelve week, randomized, double-blind, placebo-controlled trial to determine the efficacy and safety of infliximab in juvenile-onset spondyloarthritis (Jo-SpA). Ann Rheum Dis. 2008, 67 (Suppl ii): 69-70.","journal-title":"Ann Rheum Dis"},{"key":"3802_CR37","first-page":"201","volume":"9","author":"BM Ansell","year":"1991","unstructured":"Ansell BM, Hall MA, Loftus JK, Woo P, Neumann V, Harvey A, Sills JA, Swinson D, Insley J, Amos R: A multicentre pilot study of sulphasalazine in juvenile chronic arthritis. Clin Exp Rheumatol. 1991, 9: 201-203.","journal-title":"Clin Exp Rheumatol"},{"key":"3802_CR38","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1002\/1529-0131(199805)41:5<808::AID-ART6>3.0.CO;2-T","volume":"41","author":"MA Van Rossum","year":"1998","unstructured":"Van Rossum MA, Fiselier TJ, Franssen MJ, Zwinderman AH, ten Cate R, van Suijlekom-Smit LW, van Luijk WH, van Soesbergen RM, Wulffraat NM, Oostveen JC, Kuis W, Dijkstra PF, van Ede CF, Dijkmans BA: Sulfasalzin in the treatment of juvenile chronic arthritis. A randomized double-blind placebo-controlled multicenter study. Arthritis Rheum. 1998, 41: 808-816. 10.1002\/1529-0131(199805)41:5<808::AID-ART6>3.0.CO;2-T.","journal-title":"Arthritis Rheum"},{"key":"3802_CR39","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1136\/ard.61.10.941","volume":"61","author":"R Burgos-Vargas","year":"2002","unstructured":"Burgos-Vargas R, Vazquez-Mellado J, Pacheco-Tena C, Hern\u00e1ndez-Gardu\u00f1o A, Goycochea-Robles MV: A 26 week randomised, double-blind, placebo controlled exploratory study of sulfasalazine in juvenile onset spondyloarthropathies. Ann Rheum Dis. 2002, 61: 941-942. 10.1136\/ard.61.10.941.","journal-title":"Ann Rheum Dis"},{"key":"3802_CR40","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1002\/art.1780380507","volume":"38","author":"M Dougados","year":"1995","unstructured":"Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A, Cats A, Dijkmans B, Olivieri I, Pasero G, Veys EM: Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, doubleblind, placebocontrolled study. Arthritis Rheum. 1995, 38: 1218-1227. 10.1002\/art.1780380907.","journal-title":"Arthritis Rheum"},{"key":"3802_CR41","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1136\/ard.2006.052878","volume":"65","author":"J Braun","year":"2006","unstructured":"Braun J, Zochling J, Baraliakos X, Alten R, Burmester G, Grasedyck K, Brandt J, Haibel H, Hammer M, Krause A, Mielke F, Tony HP, Ebner W, G\u00f6m\u00f6r B, Hermann J, Zeidler H, Beck E, Baumgaertner M, Sieper J: Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial. Ann Rheum Dis. 2006, 65: 1147-1153. 10.1136\/ard.2006.052878.","journal-title":"Ann Rheum Dis"},{"key":"3802_CR42","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1136\/ard.2010.133645","volume":"70","author":"M Rudwaleit","year":"2011","unstructured":"Rudwaleit M, van der Heijde D, Landew\u00e9 R, Akkoc N, Brandt J, Chou CT, Dougados M, Huang F, Gu J, Kirazli Y, Van den Bosch F, Olivieri I, Roussou E, Scarpato S, S\u00f8rensen IJ, Valle-O\u00f1ate R, Weber U, Wei J, Sieper J: The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis. 2011, 70: 25-31. 10.1136\/ard.2010.133645.","journal-title":"Ann Rheum Dis"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/ar4072.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/ar4072\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/ar4072.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T06:46:35Z","timestamp":1728369995000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/ar4072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,24]]},"references-count":42,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2012,10]]}},"alternative-id":["3802"],"URL":"https:\/\/doi.org\/10.1186\/ar4072","relation":{},"ISSN":["1478-6354"],"issn-type":[{"value":"1478-6354","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10,24]]},"assertion":[{"value":"29 April 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2012","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2012","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2012","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"R230"}}